Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals awaits an FDA decision on INO-3107 with the PDUFA date set for October 30. FDA decision on INO-3107 represents a critical regulatory milestone that may substantially influence Inovio's product pipeline and market trajectory.

Inovio Pharmaceuticals nears October 30 FDA decision for INO-3107 in RRP. Upcoming FDA decision on INO-3107 holds potential to significantly shift Inovio's trajectory and investor sentiment.

Inovio Pharmaceuticals reported Q2 2026 earnings with INO-3107 on track for key development and regulatory milestones. INO-3107 progress in the pipeline can drive major shifts in company trajectory and investor sentiment.

Inovio Pharmaceuticals, Inc. held its Q2 2026 earnings call covering financial results, operational updates and forward outlook for the company. Q2 earnings updates supply financial metrics and guidance that moderately shape near-term investor expectations for INO.

Inovio Pharmaceuticals Q2 earnings call highlighted financial results, pipeline progress, and operational updates for the period. Q2 earnings details can influence short-term sentiment and valuation but rarely shift long-term trajectory alone.

Inovio Pharmaceuticals reported second quarter 2026 financial results and recent business highlights. Quarterly results and business updates provide performance data that can shift near-term investor sentiment without altering long-term company direction.

Inovio Pharmaceuticals priced a $20.0 million public offering. The offering adds cash for operations but dilutes shares and typically triggers short-term price pressure.

Inovio Pharmaceuticals, Inc. (INO) announced a proposed public offering. Proposed public offering provides capital but dilutes shares and pressures stock performance.

Inovio Pharmaceuticals shareholders voted to support the board as FDA review advances for INO-3107. Shareholder backing plus ongoing FDA review of INO-3107 creates significant momentum for pipeline progress and investor sentiment.

INOVIO's Chinese partner ApolloBio announced positive topline results from a Phase 3 trial of VGX-3100 in cervical dysplasia patients. Positive Phase 3 results for VGX-3100 advance INOVIO's core cervical dysplasia program and market prospects.

Inovio Pharmaceuticals stock edged up after hours as its partner reported success in a cervical dysplasia trial. Partner trial success offers moderate boost to Inovio market sentiment and positioning.

Inovio Pharmaceuticals, Inc. (INO) Q1 2026 earnings call summary outlines financial results, operational progress, pipeline updates, and forward guidance. Q1 2026 earnings summary highlights financial performance and pipeline advancements poised to significantly influence INO's trajectory and investor sentiment.

Inovio Pharmaceuticals (INO) Q1 2026 earnings call highlights progress in key initiatives alongside ongoing challenges impacting operations and pipeline development. Earnings highlights reveal moderate advancements offset by challenges, expected to influence financials and sentiment without fundamentally altering trajectory.

Inovio Pharmaceuticals (INO) reported first quarter 2026 financial results and recent business highlights. Quarterly financial results and business highlights signal key updates on operations, pipeline progress, and financial health that can drive significant shifts in market performance.

Inovio Pharmaceuticals (INO) released the full transcript of its Q1 2026 earnings call, detailing quarterly financial results, operational updates, and forward-looking guidance. Q1 2026 earnings call covers financial performance and strategic updates with moderate influence on INO's trajectory and market sentiment.

Moderna has overtaken Inovio Pharmaceuticals as the market's preferred Hantavirus stock due to stronger investor confidence in its platform and developments, shifting sentiment away from INO's candidates. Investor preference shifting to Moderna undermines Inovio's competitive position and stock performance in the Hantavirus vaccine market.

Inovio Pharmaceuticals (INO) reported a Q1 loss wider than expected, with sales down year-over-year due to seasonal effects. Wider-than-expected Q1 loss and year-over-year sales decline highlight moderate pressure on near-term financial performance.

Inovio Pharmaceuticals (INO) stock dropped 32.7% over the past four weeks, but technical indicators and momentum suggest a trend reversal may be imminent. INO's 32.7% four-week decline creates moderate short-term pressure on market performance, offset by signals of potential reversal.

Inovio Pharmaceuticals priced a $17.5 million underwritten public offering of 12.5 million shares of common stock and warrants at $1.40 per share and accompanying warrant. $17.5 million public offering raises critical capital for R&D but dilutes existing shareholders, significantly impacting financial position and stock performance.

Inovio Pharmaceuticals, Inc. (INO) announces a proposed public offering of its common stock. Proposed public offering enables capital raise for operations but dilutes existing shares, significantly influencing stock price and financial trajectory.

Inovio Pharmaceuticals, Inc. released Q4 2025 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Q4 earnings summary impacts financial performance and investor sentiment but balanced by ongoing clinical and market factors.

Inovio Pharmaceuticals Inc (INO) Q4 2025 earnings call highlights strategic moves advancing pipeline, financial position, and partnerships. Strategic moves in Q4 2025 earnings call signal major shifts in pipeline and partnerships, poised to significantly alter INO's trajectory and investor sentiment.

Inovio Pharmaceuticals released highlights from its Q4 earnings call, covering financial results, pipeline updates, and strategic outlook. Q4 earnings call highlights disclose financial performance, clinical progress, and strategic plans significantly shaping Inovio's market trajectory.

INOVIO Pharmaceuticals reported fourth quarter and full-year 2025 financial results, highlighting recent business developments. Quarterly and annual earnings releases with business highlights directly influence financial performance metrics, investor sentiment, and stock trajectory.

Inovio Pharmaceuticals (INO) released Q4 earnings snapshot detailing financial results. Q4 earnings snapshots moderately influence financial performance and investor sentiment for biotech companies like Inovio.

Akeso and INOVIO announce clinical collaboration to advance novel combination therapy for glioblastoma (GBM). Clinical collaboration with Akeso advances INO's oncology pipeline in high-unmet-need GBM, signaling major strategic progress with potential to significantly enhance competitive positioning and investor sentiment.

INOVIO and Akeso announce clinical collaboration to advance novel combination therapy for glioblastoma (GBM). Clinical collaboration with Akeso expands Inovio's oncology pipeline into high-need glioblastoma treatment, signaling major strategic partnership with potential to enhance competitive positioning and investor sentiment.

Inovio Pharmaceuticals highlights FDA acceptance of its INO-3107 BLA, with upcoming FDA discussions ahead of the October 30 PDUFA decision date. FDA BLA acceptance and PDUFA date for INO-3107 represent a potential regulatory approval that could fundamentally redefine Inovio's competitive position and long-term prospects.

Inovio Pharmaceuticals (INO) stock faces potential plunge to $0 amid persistent clinical trial failures, funding shortages, and leadership turmoil eroding investor confidence. Headline speculation of stock hitting zero highlights existential risks from operational failures and cash burn, likely shifting investor sentiment dramatically.

Inovio Pharmaceuticals, Inc. will participate in several upcoming scientific and investor conferences, showcasing its advancements in DNA medicines and immunotherapy. The company aims to engage with investors and the scientific community to discuss its pipeline and strategic initiatives. Participation in conferences can enhance visibility and investor interest, but the immediate impact on financial performance is expected to be limited.